



Children's Rights

GRI Standards:

408-1: Child Labor

EXECUTIVE SUMMARY

Sanofi's commitment to respect and promote children's rights is a constituent part of our human rights vision and approach. Its aim is to align with the **Ten Children's Rights and Business Principles**⁽¹⁾ developed by UNICEF in March 2012, together with the United Nations (UN) Global Compact and Save the Children.

This factsheet describes Sanofi's commitments to address each of these ten principles, applicable in all countries where it operates or acts with particular attention to protecting and improving their health and access to health care for all children.

¹ The first comprehensive guidance to companies on how to integrate children's rights into their policies and business processes.

TABLE OF CONTENTS

<i>1. Principle 1: All businesses should meet their responsibility to respect children’s rights and commit to supporting the human rights of children</i>	<i>5</i>
1.1. A COMMITMENT EMBEDDED IN OUR HUMAN RIGHTS STATEMENT AND APPROACH	5
1.2. WHAT ARE CHILDREN’S RIGHTS FOR SANOFI?	5
1.3. RAISING AWARENESS ABOUT THE IMPACT OF HUMAN AND CHILDREN’S RIGHTS ON OUR VALUE CHAIN	5
<i>2. Principle 2: All businesses should contribute to the elimination of child labor, including in all business activities and business relationships</i>	<i>6</i>
2.1. ADOPTION OF A POLICY ON CHILD LABOR	6
2.2. OUR COMMITMENT TO ELIMINATE CHILD LABOR IS ALSO EXPRESSED IN OUR INTERNAL REFERENCE DOCUMENTS	6
2.3. ESTABLISHING GRIEVANCE MECHANISMS	7
2.4. IMPLEMENTING A DUE DILIGENCE PROCESS	7
<i>3. Principle 3: All businesses should provide decent work for young workers, parents and caregivers</i>	<i>7</i>
3.1. PROVIDING OUR EMPLOYEES WITH A DECENT STANDARD OF LIVING	7
3.2. IMPROVING EMPLOYEES’ WORK-LIFE BALANCE	8
ENFANTS DE SANOFI: SUPPORTING OUR EMPLOYEES’ CHILDREN AND FAMILIES	8

4. Principle 4: All businesses should ensure the protection and safety of children in all business activities and facilities
9

4.1. IN OUR BUSINESS ACTIVITIES: PROTECTING CHILDREN PARTICIPATING IN SANOFI’S CLINICAL TRIALS..... 9

4.2. IN OUR FACILITIES: ENSURING THE SAFETY OF YOUNG WORKERS
9

5. Principle 5: All businesses should ensure that products and services are safe and seek to support children’s rights through them..... 9

5.1. A LARGE PORTFOLIO OF MEDICINES COVERING A WIDE RANGE OF PEDIATRIC HEALTH ISSUES 10

5.2. SANOFI VACCINES: IMMUNIZING CHILDREN AGAINST VACCINE-PREVENTABLE DISEASES 11

6. Principle 6: All businesses should use marketing and advertising that respect and support children’s rights12

7. Principle 7: All businesses should respect and support children’s rights in relation to the environment and to land acquisition and use12

8. Principle 8: All businesses should respect and support children’s rights in security arrangements13

9. Principle 9: All businesses should help protect children affected by emergencies.....13

10.Principle 10: All businesses should reinforce community and government efforts to protect and fulfill children’s rights
14

10.1. FIGHTING CHILDHOOD CANCER 14
10.2. RAISING AWARENESS ABOUT DIABETES..... 15

1. Principle 1: All businesses should meet their responsibility to respect children's rights and commit to supporting the human rights of children

1.1. A COMMITMENT EMBEDDED IN OUR HUMAN RIGHTS STATEMENT AND APPROACH

Sanofi's commitment to respect children's rights is embedded into the business from the top, through the endorsement of Sanofi's human rights statement by the Senior Vice President in charge of Corporate Social Responsibility (CSR).

The statement specifies that as a multinational healthcare company keenly aware of its social responsibility; Sanofi is committed to integrating respect for human rights into all its business operations and public positions. We are convinced that, while states and governments have a duty to protect human rights through adequate laws and policies, businesses also have a role to play, which begins with identifying their own impacts on human rights and taking measures to prevent human rights violations.

Among other relevant international standards, Sanofi is committed to upholding the two emerging international reference frameworks that are the United Nations Guiding Principles on Business and Human Rights and The Children's Rights and Business Principles developed by UNICEF, the United Nations Global Compact and Save the Children.

Sanofi's commitment to respect human rights is the foundation of our CSR approach. It provides Sanofi with an inspirational framework and guide for analysis and action towards continuous improvement in our CSR pillars. In line with the United Nations Guiding Principles, Sanofi pays a particular attention to the rights and needs of, as well as the challenges faced by, groups or populations that may be especially vulnerable, such as children.

1.2. WHAT ARE CHILDREN'S RIGHTS FOR SANOFI?

As a global healthcare leader operating in over 100 countries, the Company brings heightened attention to:

- **human rights at work**, including the right to safe working conditions and the elimination of child labor, whether for Sanofi's employees or those of its suppliers and business partners;
- **the right to health**, and all human rights related to, or constitutive of, this right, such as access to healthcare or the issue of pharmaceuticals in the environment. Children under the age of 18 account for nearly one-third of the global population, and we are committed to protecting and improving their health, and support governments and other stakeholders' efforts to reduce the barriers to access to healthcare for children; and
- **the whole spectrum of human rights of patients and clinical trial participants**, going beyond the right to health to encompass, for instance, the right to access information or the right to privacy.

1.3. RAISING AWARENESS ABOUT THE IMPACT OF HUMAN AND CHILDREN'S RIGHTS ON OUR VALUE CHAIN

Since 2013, the company issued an awareness-raising guide, Human Rights in our Activities, for all its employees.

Built from the results of the participatory self-assessment conducted at company level, the Human Rights in our Activities guide maps Sanofi's potential human rights impacts along the four steps of a drug's lifecycle, with a transverse section on human rights at work, including issues related to child labor.

It was designed with four aims:

- to inform and familiarize all Sanofi employees with the key concepts and principles of respect for human rights;
- to raise awareness about the spectrum of human rights risks related to the functional responsibilities of our personnel and business partners;
- to describe a selection of relevant best practices implemented at Sanofi; and
- to act as a reference point for Sanofi managers making decisions about potential issues linked to human rights in their daily activity.

The Human Rights in our Activities guide is deployed through internal tools such as a slide kit for managers and a dedicated website to help Sanofi managers better understand their role and responsibilities in applying human rights principles.

For more information, see our in the [Document Center](#): the Human Rights in our Activities guide and The Human Rights Due Diligence Factsheet

2. Principle 2: All businesses should contribute to the elimination of child labor, including in all business activities and business relationships

2.1. ADOPTION OF A POLICY ON CHILD LABOR

Since 2015, we have continued our human rights due diligence process in line with the UN guiding principles with a focus on strengthening our internal guidelines on human rights at work.

We therefore integrated human rights in our internal control manual with the implementation of a dedicated control covering child labor and put in place human rights training for the internal auditors covering the Europe, Africa, Middle East and South Asia regions.

In order to ensure a common understanding of this control across the company, a global policy on Child Labor Policy was released in 2015.

According to our Child Labor Policy, Sanofi commits to respect at a minimum the provisions of the International Labour Organization (ILO) conventions 138 and 182 on the prohibition of child labor, without prejudice to more favorable national provisions. It rejects all forms of child labor as defined by these international labor standards and requires its suppliers to comply with the same standards.

This means that:

- (1) Sanofi is not engaged in and does not support any form of child labor;
- (2) employment of persons under the age of 15 or under the legal age for finishing compulsory schooling is prohibited; and
- (3) no hazardous work can be performed by a person under the age of 18.

This global policy applies to all Sanofi corporate functions, regions, countries and divisions worldwide. Specific measures must be defined to implement this policy in the supply chain.

For more information, see our [Document Center](#): Fundamental Human Rights at Work Factsheet.

2.2. OUR COMMITMENT TO ELIMINATE CHILD LABOR IS ALSO EXPRESSED IN OUR INTERNAL REFERENCE DOCUMENTS

The human rights principles and Sanofi's commitments, including those applicable to children, which Sanofi upholds, are also listed in our key internal reference documents, such as:

- the Social Charter;
- the Code of Conduct; and

- the Suppliers' Code of Conduct.

These documents present human rights as a core element of Sanofi's company values and contribute to embedding human and children's rights in our company culture. The Sanofi Social Charter, for instance, sets out employees' fundamental rights in accordance with the relevant ILO conventions related to child labor:

- C138: Minimum Age Convention, 1973; and
- C182: Worst Forms of Child Labour Convention, 1999.

They also set forth our expectations towards our stakeholders to meet their responsibility to respect human rights — explicitly stating that the mentioned criteria are to be considered as the minimum applicable standard should local regulations be less stringent in any of Sanofi's countries of operation.

In addition, Sanofi's Suppliers' Code of Conduct stipulates that:

- the minimum working age must never be less than 15 years of age, regardless of the type of activity; and
- the minimum age of employment for labor which, due to its nature or to the conditions in which it is exercised, may jeopardize the health, safety or morality of children or teenagers, must never be less than 18 years of age.

Every employee must therefore be aware of and commit to individually respect principles of the reference documents upheld by Sanofi, both internally and externally.

For more information, see our [Document Center](#): Code of Conduct, Suppliers Code of Conduct, Social Charter.

2.3. ESTABLISHING GRIEVANCE MECHANISMS

As described in the Code of Conduct, any employee must inform his or her superior or the Ethics & Business Integrity Department representative of any case or suspected case of child labor.

2.4. IMPLEMENTING A DUE DILIGENCE PROCESS

Sanofi implements a global "child labor" due diligence process:

- at every level of the Company, vigilance must be reinforced to ensure appropriate mitigation of the risk of use or benefit from child labor;
- adequate internal control measures must be in place to ensure no use of child labor; and
- the Procurement Risk Management Model must identify and assess suppliers according to their respect of the prohibition of child labor.

3. Principle 3: All businesses should provide decent work for young workers, parents and caregivers

3.1. PROVIDING OUR EMPLOYEES WITH A DECENT STANDARD OF LIVING

Sanofi's compensation policy aims at providing wages that are sufficient to cover employees' basic needs (food, children's education, family expenditure on goods and services, etc.), thus contributing indirectly to the avoidance of child labor, often used as a complementary resort to compensate family revenue.

Sanofi also seeks to provide all employees worldwide with high-quality benefits covering health, pension, incapacity, disability, and death. In all countries, employees (as well as, in general, their spouses and children) receive reasonable reimbursements of medical expenses, as well as death benefits.

For more information, see our [Publications](#): section 3.3.1.4.1.2. High quality employee benefits, in the Declaration of Extra-Financial Performance.

3.2. IMPROVING EMPLOYEES' WORK-LIFE BALANCE

Sanofi is committed to improving the work-life balance of its employees, including those who are parents. We are aware of the challenge of managing work accountabilities and career aspirations while handling parenthood and associated responsibilities. In line with our D&I strategy, we are rolling out a global standard for inclusive and equal parental leave. Since 2022, Sanofi grants 14 weeks paid parental leave to any Sanofi employee welcoming a new child through childbirth or adoption, no matter which country they are working in and irrespective of gender or sexual orientation, as long as the employee is recognized as the child's parent as per local legislation or practice.

Since pioneering this policy in Latin America in 2020, we have seen first-hand the concrete and positive impact it can have for employees becoming parents. It gives our employees the freedom to determine the childcare arrangements that work best for them as a family and provide quality time to better bond together: a step forward for driving equality in the workplace and greater choices beyond.

In line with our DEI strategy, a well-balanced, flexible workplace is essential for maintaining an inclusive culture, which caters to individual needs and working styles. Local situations and regulations differ, so there is no "one-size-fits-all". The key is to strike the right balance between human work interaction and technology-enabled remoteness. Sanofi is committed to offering flexible work globally, providing a set of global guidelines for local execution in accordance with business needs and local laws.

For more information, our [Document Center](#): Diversity and Inclusion factsheet; and see our [Publications](#): section 3.3.1.5. Creating our Diversity Edge, in the Declaration of Extra-Financial Performance.

ENFANTS DE SANOFI: SUPPORTING OUR EMPLOYEES' CHILDREN AND FAMILIES

Sanofi is committed to helping employees' children up to the age of 25 who are experiencing difficulties as a result of medical problems, educational difficulties, or social and family troubles.

Sanofi's *Enfants de Sanofi* program is an association under French law (charitable organization) that provides individual support to our employees' families worldwide by responding to individual requests, and also takes collective actions in many subsidiaries like vaccination, dental care, and eyesight test campaigns and educational programs.

In 2022, *Enfants de Sanofi* supported 132 employees' children in 27 countries, and organized collective actions in 11 countries for 3 295 children such as:

- vaccinations in the Philippines and Vietnam;
- medical checkups in China;
- sight tests in Hungary;
- special support in Ukraine and Turkey;

For more information, see [Enfants de Sanofi, Rapport Annuel 2022](#).

4. Principle 4: All businesses should ensure the protection and safety of children in all business activities and facilities

4.1. IN OUR BUSINESS ACTIVITIES: PROTECTING CHILDREN PARTICIPATING IN SANOFI'S CLINICAL TRIALS

We are committed to conducting exemplary clinical trials worldwide by applying the most stringent quality standards. Our responsibility is also to ensure that all participants in clinical trial programs have provided genuine, individual, informed consent.

More specifically, we make a particular effort to ensure that children's fundamental rights, such as the right to information on the benefits and risks prior to giving consent, are respected and protected. We engage in different kinds of actions:

- Sanofi provides specific texts to children that explain the rules of informed consent in a simple and understandable way.
- Sanofi has set up specific tools tailored to children, such as adapted pain scales.

For example, Sanofi France produced a film for people who are considering taking part in a clinical trial, including in pediatric clinical trials, which explains the rules of informed consent, gives trial-related information, and describes the documents that must be delivered to patients, the restrictions, and the importance of taking one's time to decide.

4.2. IN OUR FACILITIES: ENSURING THE SAFETY OF YOUNG WORKERS

Through its health and safety policy, Sanofi deploys actions and measures to safeguard the physical and mental health of all employees, including young workers as permitted by Sanofi's internal reference documents, by minimizing their exposure to chemical, biological and physical factors, and by taking measures to ensure their well-being at work.

As described above, the Suppliers' Code of Conduct, which refers among other instruments to the ILO conventions on child labor, sets out the standards we expect our suppliers to comply with in order to fight against child labor and protect workers' health and safety. The minimum age for employment is set at 15 years; workers under the age of 18 shall not perform tasks that are likely to jeopardize their health, safety or morality.

For more information, our [Document Center](#): *Health and Safety in the Workplace factsheet*; and see our [Publications](#): 3.4.14. *Procurement and subcontracting, in the Declaration of Extra-Financial Performance*.

5. Principle 5: All businesses should ensure that products and services are safe and seek to support children's rights through them

Finding innovative solutions to improve access to quality healthcare, including to essential medicines and vaccines, is an everyday objective for Sanofi.

Sanofi pays particular attention to the rights and needs of, as well as the challenges faced by, children.

5.1. A LARGE PORTFOLIO OF MEDICINES COVERING A WIDE RANGE OF PEDIATRIC HEALTH ISSUES

Today, Sanofi's portfolio covers a large part of the molecules and vaccines in the World Health Organization's (WHO) list of essential medicines for children:

- prevention (pediatric, meningococcal and rabies vaccination);
- acute infections (respiratory, gastrointestinal and urinary infections; typhoid fever; meningitis; pain and fever);
- endemic disease (malaria, tuberculosis, sleeping sickness, leishmaniasis);
- chronic disease (epilepsy, diabetes, allergies); and
- genetic disease (rare diseases).

We provide medication and healthcare tools to address numerous fundamental childhood health issues, from the routine to the life-threatening, offering major therapeutic solutions in many areas of pediatrics, such as: pain and fever; gastrointestinal disorders and parasitology; allergic and respiratory diseases; epilepsy, diabetes and vaccine-preventable diseases.

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

RSV is the most common cause of lower respiratory tract infections (LRTI), including bronchiolitis and pneumonia in infants.⁽²⁾ It is also a leading cause of hospitalization in all infants, with most hospitalizations for RSV occurring in healthy infants born at term.⁽³⁾ Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalizations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years.⁽⁴⁾

Nirsevimab, a long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly by Sanofi and AstraZeneca. Nirsevimab has been developed to offer newborns and infants direct RSV protection via an antibody to help prevent medically attended lower respiratory tract infections caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against the disease.⁽⁵⁾ Data from the HARMONIE Phase 3b clinical trial have shown an 83.21% (95% CI 67.77 to 92.04; P<0.001) reduction in hospitalizations due to RSV-related LRTD in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.⁽⁶⁾

The Hospitalized RSV Monoclonal Antibody Prevention (HARMONIE) study is a large, multi-country European interventional clinical trial aiming to determine the efficacy and safety of a single intramuscular dose of nirsevimab, with data collected in a real-world setting during the 2022-2023 RSV season⁽⁷⁾. The trial

² R K. Respiratory Syncytial Virus Vaccines. Plotkin SA, Orenstein WA, Offitt PA, Edwards KM, eds Plotkin's Vaccines 7th ed Philadelphia. 2018;7th ed. Philadelphia:943-9.

³ Leader S, Kohlhasse K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. The Pediatric infectious disease journal. 2002;21(7):629-32.

⁴ Shi T, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390:946-58.

⁵ Centers for Disease Control and Prevention. Vaccines & Immunizations. August 18, 2017. <https://www.cdc.gov/vaccines/vac-gen/immunity-types.htm>. Accessed May 2023.

⁶ Smith DK, et al. Respiratory Syncytial Virus Bronchiolitis in Children. *Am Fam Physician*. 2017;95(2):94-99.

⁷ Drysdale S, et al. Efficacy of nirsevimab against RSV lower respiratory tract infection hospitalization in infants: preliminary data from the HARMONIE phase 3b trial. Presented at 41st Annual Meeting of the European Society for Paediatric Infectious Diseases in Lisbon, 2023.

recruited more than 8,000 infants and took place at nearly 250 sites across France, Germany and the United Kingdom. The data from HARMONIE were presented at the 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Beyfortus has been approved for use in the European Union, the US, China, Japan, and many other countries around the world. Special designations to facilitate expedited development of Beyfortus were granted by several regulatory agencies, including Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products Administration; Breakthrough Therapy Designation and Fast Track Designation from the US Food and Drug Administration; access granted to the European Medicines Agency (EMA) PRiority MEdicines (PRIME) scheme and EMA accelerated assessment; Promising Innovative Medicine designation by the UK Medicines and Healthcare products Regulatory Agency; and Beyfortus has been named “a medicine for prioritized development” under the Project for Drug Selection to Promote New Drug Development in Pediatrics by the Japan Agency for Medical Research and Development.

For more information, see the [Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting](#)

5.2. SANOFI VACCINES: IMMUNIZING CHILDREN AGAINST VACCINE-PREVENTABLE DISEASES

Close to 20 million children do not receive a full course of even basic vaccines, and many more miss out on newer vaccines. Of these, over 14 million “zero dose” children receive no vaccines through immunization programmes at all⁽⁸⁾. At the same time, in other parts of the world, including high-income countries, the benefit of vaccination is becoming less obvious to some populations. Because of lower vaccination coverage, we see the resurgence of diseases that had almost disappeared, such as measles or pertussis.

Access to vaccination is hampered by multiple barriers that may be structural (e.g., health systems, conflicts, affordability, etc.) or societal (behaviors, education, beliefs). This multifactorial challenge can only be addressed by committed partnerships between all the actors with a stake in the sustained success of vaccination and prevention programs.

True to our vision of a world where no one suffers or dies from a vaccine-preventable disease, Sanofi is committed to working on multiple levels to optimize the impact of vaccination:

- developing a broad portfolio of vaccines and solutions to address worldwide epidemiological challenges;
- playing an active role in key public-private partnerships;
- providing effective and affordable vaccines and protection to all populations, regardless of their level of wealth; and
- contributing to local capacity building of healthcare systems to prevent infectious diseases.

Polio eradication is in sight



⁸ World health Organization Explaining the Immunization Agenda 2030, [Explaining the Immunization Agenda 2030 \(who.int\)](#)

Polio is a contagious disease that mainly affects children under five. One in 200 infections leads to irreversible paralysis. Over the last 30 years, under the Global Polio Eradication Initiative (GPEI), 2.5 billion children have been immunized against polio resulting in a 99% reduction in the number of cases worldwide. At the end of 2023, polio was endemic in only two countries (Afghanistan and Pakistan) with 12 wild polio virus cases reported (compared with 30 in 2022). As a result of the global effort to eradicate the disease, almost 20 million people have been saved from paralysis.

The polio strategy aims for all polio viruses to have been sustainably eradicated worldwide – meaning no cases have been detected for three years – by 2026. Since 1988, Sanofi has been a key partner of the Global Polio Eradication Initiative and has supplied more than 14 billion doses of Oral Polio Vaccine (OPV) and 1.5 billion doses of Inactivated Polio Vaccine (IPV) in the world. In 2023, Sanofi supplied a total of 35 million doses of IPV vaccine to UNICEF for GAVI countries. In addition, 27 million doses of polio vaccine were provided to Brazil, India, Indonesia and the Philippines.

Sanofi has expanded its IPV production capacities and is in a position to contribute greatly to the demand of doses needed for this unprecedented global rollout of polio vaccination. Between 2014 and 2023, Sanofi supplied 430 million IPV doses to UNICEF.

6. Principle 6: All businesses should use marketing and advertising that respect and support children's rights

Sanofi is committed to ethical marketing practices through:

- the adherence to the codes governing our industry in Europe (EFPIA), the United States (PhRMA) and worldwide (IFPMA); and
- our own internal codes governing our promotional activities.

Our overarching concern is ensuring patient safety and the proper use of our products. In the marketing of our products, including drugs available without a prescription, we are committed to provide accurate, complete and reliable information to physicians, pharmacists and other healthcare professionals. All our promotional materials are based on scientifically proven results and undergo an internal (by the Global Quality Direction) and external (by health authorities) review process, in order to ensure that the information provided is objective and fair.

7. Principle 7: All businesses should respect and support children's rights in relation to the environment and to land acquisition and use

To safeguard the health of communities and of children everywhere, we continually seek to limit the environmental impact of our activities along the entire life cycle of our products, from development through marketing, and monitoring pharmaceuticals in the environment.

Because Sanofi believes that reducing greenhouse gas emissions and using energy responsibly are part of our mission to help protect life on the planet, we are committed to optimizing our energy consumption and energy security, and reducing our carbon footprint. We are also committed to managing water responsibly in the interest of future generations and their continued access to the resource.

Pharmaceuticals found in the environment due to human activity — such as patients' disposal of medicines or effluents from drug production facilities — are the focus of growing attention. Even in trace amounts, their presence represents a potential health concern for adults and children alike, and this is a challenge that Sanofi takes seriously. Sanofi addresses this challenge through a multifaceted program ranging from supporting take back programs of unused medicines to implementing cutting-edge technologies to reduce discharge from our chemical and pharmaceutical sites in India, for example.

8. Principle 8: All businesses should respect and support children's rights in security arrangements

Sanofi does not use public forces to ensure the security of its premises.

When necessary, Sanofi hires private security forces, and ensures that their behavior is in line with Sanofi's security policy, which includes respect for children's rights.

9. Principle 9: All businesses should help protect children affected by emergencies

Foundation S provides humanitarian aid to communities and displaced populations during times of emergency and crises. Through multiple partnerships such as with TULIPE or Direct Relief, Foundation S provides medicine donations to countries around the world.

Since its inauguration in 2022, Foundation S has completed 63 donations, combining all types of donations for more than €50 million, including the equivalent of 53 million daily treatments of essential medicines to treat 22 million patients. In 2023, Foundation S orchestrated directly or through partners more than 30 donations including in Ukraine, Sri Lanka, Lebanon, Morocco, Turkey, Honduras, Dominican Republic, Mexico, India and South Korea. In particular, Foundation S worked with TULIPE to contribute to medicine donations for Sudanese refugees in Chad and to populations in Nogorno-Karabakh.

Donations in 2023 included:

- 8 donations to Ukraine: via several channels (directly, or with TULIPE or RARS(1)), Foundation S continued donating medicines and vaccines to support Ukrainian patients and refugees. Up to three million daily treatments of various essential medicines, including breast cancer treatments and vaccines, were donated in 2023 to treat 10,000 patients.
- Turkey and North Syria (earthquake in February 2023): through AFAD, Turkish Red Crescent (Turk Kizilay), AKUT, PUI, WHO and UNHCR, Foundation S provided support of up to €4 million to displaced and impacted people and communities. Donations included:
 - 100,000 doses of diphtheria / tetanus vaccines;
 - 125,000 units of essential medicines; and
 - cash donation to NGOs

These donations were equivalent to 2.2 million daily treatments, reaching approximately 150,000 people.

- Sri Lanka: Foundation S orchestrated the donation of 600,000 kits of CLEXANE to treat 60,000 patients in Sri Lanka through Direct Relief, for a total value of up to €6.3 million.
- Morocco (September 2023 earthquake): through the King's Fund, Foundation S provided support of up to €1 million to support displaced and impacted people and communities. In addition, matching funding resulted in an additional cash donation of up to €72,000 to the Red Crescent in Morocco.
- One donation completed to ANERA in Lebanon for Palestinian refugees representing 114,000 daily treatments to treat 4,000 patients.
- One donation completed in December 2023, to support population impacted in Mexico by the OTIS Hurricane with General Medicines, Vaccines and Consumer Healthcare products equivalent 500,000 daily treatments to treat 140,000 patients.
- 5 donations completed in the Gaza Israel area, equivalent 120,000 daily treatments for 13,000 patients.

10. Principle 10: All businesses should reinforce community and government efforts to protect and fulfill children's rights

Sanofi participates in numerous projects, in close cooperation with local governments and institutions, to protect and fulfill children's right to health and education.

10.1. FIGHTING CHILDHOOD CANCER

Worldwide, nearly 400,000 cases of cancer are diagnosed in children under the age of 19 every year. Nearly 80% of them live in countries with limited resources where survival rates are as low as 20% to 30%, while in the US and other developed nations 80% of children with cancer survive. The 'My Child Matters' program (MCM) was launched in 2005 to increase childhood cancer survival rates by providing financial support to families and children living with cancer. The program aims to act in three main dimensions in LMICs :

1. Strengthen healthcare systems by improving their ability to diagnose and treat childhood cancers.
2. Support the families to avoid treatment abandonment.
3. Take care of children with cancer through pain management, palliative care or access to services.

The program focuses on training healthcare professionals, improving data collection through cancer registries, raising public awareness, improving the quality and speed of diagnosis, ensuring treatment continuation and adherence, and improving access to and the delivery of pain relief and palliative care. MCM is a collaboration between partners such as the Groupe Franco-Africain d'Oncologie Pédiatrique (GFAOP), the International Society of Pediatric Oncology (SIOP), numerous non-governmental organizations (NGOs), and healthcare experts from hospitals across the world. Since 2005, My Child Matters has provided support to 51 hospitals and NGOs in 33 countries, helping more than 140,000 children, and training over 40,000 healthcare professionals. The program has been credited with considerably increasing survival outcomes.

To foster best-practice sharing between experts and countries, the MCM program launched an open data platform in 2022. The aim is to highlight all MCM programs globally and to ensure all stakeholders fighting childhood cancer can benefit from critical data, know-how and the most recent scientific publications in pediatric oncology. In the last year, two main updates on the MCM open data platform were the addition of a publications library and dedicated pages for local projects.

Cancer remains the leading cause of death from disease in children in the developed world, and most of the medicines we use to treat childhood cancer today were approved decades ago. While some progress has been made in improving survival rates for certain types of childhood cancer, there remains an unmet medical need, with many survivors experiencing severe long-term side effects. Developing innovative treatments for childhood cancers is challenging due to their rarity and regulatory concerns, resulting in significant delays in making new therapies available for children⁸. The median time between the first adult trial and the first child trial is currently 6.5 years⁹. As part of its CSR strategy, Sanofi is committed to addressing childhood cancer through a three-pillar approach:

1. Developing innovative treatments: Sanofi aims to develop highly effective and safe treatments to improve outcomes for children with cancer and to reduce clinical trial delays for children. Leveraging its R&D capabilities, Sanofi focuses on its late research and early development pipeline for the timely completion of preclinical studies and the initiation of clinical trials. In November 2023, Sanofi was therefore able to dose the first pediatric patient with one of its assets, less than two years after this same asset had been dosed in the first adult patient.

⁸ European Journal of Cancer, Volume 112, May 2019, Pages 49-56.

⁹ The Lancet, Volume 7, February 2023, Pages 214-222

2. Closing knowledge gaps: Sanofi's second pillar focuses on better understanding childhood cancer and its resistance to standard treatments. This involves leveraging internal programs like the Sanofi i-awards for which a first dedicated project for childhood cancer was selected in November 2023. Sanofi also engages in partnerships with experts from renowned institutions, and with consortia. Partnerships engaged in since 2021 include those with experts from the MD Anderson Cancer Center and with institutions like the Innovative Therapies for Children with Cancer (ITCC) consortium, the Innovative Therapies for Children with Cancer's Pediatric Preclinical Proof of Concept Platform (ITCCP4), and the FNIH Convening Experts in Oncology to Address Children's Health (COACH). In September 2023, Sanofi and ITCC/Institut Gustave Roussy started building a multi-stakeholder Childhood Cancer Working Group at the Paris Saclay Cancer Cluster (PSCC) to tap into PSCC's impressive infrastructure (data, samples, models) and propose relevant research projects.

3. Raising awareness: We collaborate with patient advocacy groups (e.g. MIB Agents and Imagine for Margo) to embed patient insights into healthcare solutions, and participating in various awareness initiatives including symposia, webinars, and training courses. Sanofi's childhood cancer project team works closely with the Foundation S My Child Matters project team.

10.2. RAISING AWARENESS ABOUT DIABETES

In 2021, the International Diabetes Federation estimated that 537 million adults and 1.2 million children were living with diabetes. Rising rates of obesity and reduced physical exercise mean that type 2 diabetes is affecting people at ever younger ages, making it a global public health issue with serious consequences. Since 2021, the new WHO Global Compact to speed up action to tackle diabetes called on nation states to expand education at community level to improve understanding of diabetes, and of how it can be prevented and treated.

School plays an important role in supporting these children, but for many of them, a lack of knowledge about diabetes within schools can lead to feelings of isolation, stigmatization and discrimination.

Kids and Diabetes in Schools (KiDS), a far-reaching educational project initiated in 2013 by the International Diabetes Federation (IDF), the International Society for Pediatric and Adolescent Diabetes (ISPAD) and Sanofi, aims to bring diabetes education to schools to fight diabetes-related stigma and promote healthy lifestyles to tackle the preventable risk factors for type 2 diabetes. The KiDS project operates in each country through partnerships with various parties, such as governmental authorities, patient groups, learned societies and NGOs.

Sanofi's partners organize briefings and schools-based activities, based on core messages delivered through educational material comprising information and awareness packs for teachers and school staff, and for schoolchildren aged 6-14 and their parents; these include a guide to nutrition and diabetes, and the NutriQuiz online game. This material is culturally adapted and translated for the target audience. The KiDS program also encourages local and national decision-makers to pursue local policy changes regarding the management of type 1 diabetes and prevention strategies for type 2 diabetes in children.

Since its inception, [KiDS](#) – Kids & Diabetes in Schools – has engaged 340 000 of children and 19 800 teachers around the world. Comprehensive diabetes education and awareness programs have been rolled out in 2100 schools across more than 20 countries in partnership with local healthcare and education agencies.

The most recent countries to launch KiDS are Canada, China and Ghana. In addition, more than 45 countries have had ad-hoc KiDS sessions in school communities and this number continues to increase.

To take an example, Sanofi India has partnered with the Department of Health and Education, Government of Goa, along with its' implementing partner Conexus, to run the KiDS program since 2019. To make the program sustainable, almost 80 doctors attached to government schools have been trained to recognize Type 1 diabetes and to treat non-communicable diseases. Teams have also conducted engaging programs to promote healthier lifestyles. These include STEP program, under which a child and adult complete 10,000 steps a day, and Sakhar Free Shukrawar (Sugar Free Fridays), a unique cooking competition where children substitute healthier alternatives to sugar.

An extensive [impact assessment](#) on KiDS in India was conducted in 2023 which underlined the program's power as a catalyst for change. Also in 2023, KiDS was showcased at the World Non-Communicable

Diseases Congress in Toronto, Canada. In addition, the Indian Chamber of Commerce recognized KiDS with a Social Impact Award in 2024.